ANGIODYNAMICS INC — Form 8-K
Filed July 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
AngioDynamics reported FY2026 pro forma net sales of $320.2M (+9.4% YoY), with Med Tech segment sales of $150.0M (+18.4% YoY) and Med Device sales of $170.2M (+2.5% YoY). The company achieved pro forma adjusted EBITDA of $13.2M (vs. $7.6M prior year) and maintained a debt-free balance sheet with $53.9M cash. Key milestones include FDA IDE approvals for APEX-Return, PAVE, and RELIEF studies; Palmetto GBA Medicare coverage for NanoKnife; and Category I CPT codes effective January 2026. FY2027 guidance: $336.0M–$341.0M revenue, Med Tech growth 12–15%, adjusted EBITDA $13.0M–$16.0M.
Why this rating
Solid growth and profitability improvement are encouraging for a $245M company; Med Tech momentum (18.4%) and multiple clinical/regulatory wins strengthen pipeline. However, absolute EBITDA ($13.2M ≈5.4% of market cap) remains modest, and guidance suggests slower growth ahead. Material but not transformational.
See more from July 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.